Gilead Sciences (GILD) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $146.85 +1.82%
EPS Growth %: -14.2%
Financial Fact:
Net loss attributable to noncontrolling interest: -5M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -14.2%
Financial Fact:
Net loss attributable to noncontrolling interest: -5M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.01, $0.05 better than the analyst estimate of $1.96. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.97 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $7.95-$8.25, versus the consensus of $8.00. Gilead Sciences sees FY2025 revenue of $28.3-28.7 billion, versus the consensus of $28.7 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Gilead Sciences (GILD) PT Lowered to $163 at Morgan Stanley
- Clean Air Metals plans C$150,000 flow-through share offering
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
